---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-25-000002"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2025-01-02T23:59:59+00:00"
generated_at: "2026-05-28T18:16:44.514690+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Caribou Biosciences appoints Sri Ryali as CFO, effective January 2, 2025

## Summary
- Sri Ryali named CFO; brings 20 years biopharma finance experience; most recently CFO of Codexis.
- Ryan Fischesser ceases as interim principal financial officer and accounting officer; remains VP Finance.
- Ryali receives $485k base salary, 40% target bonus, and option to purchase 300k shares vesting over 4 years.
- Company highlights four clinical-stage programs for hematologic malignancies and autoimmune diseases; expects multiple datasets in 2025.

## SEC filing metadata
- accession: 0001619856-25-000002
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2025-01-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000002/0001619856-25-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000002/crbu-20250102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-25-000002
- JSON: https://secwatch.observer/filing/0001619856-25-000002.json
- Plain text: https://secwatch.observer/filing/0001619856-25-000002.txt

## Key facts
- Executive change
  Sriram Ryali was appointed as Chief Financial Officer at Caribou Biosciences, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On January 2, 2025, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), announced the appointment of Sriram Ryali, age 44, to the position of Chief Financial Officer (“CFO”) of the Company, effective as of January 2, 2025 (the “Start Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000002/0001619856-25-000002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.